SCHEDULE 13G/A 0001574139 XXXXXXXX LIVE 1 Common Stock, par value $0.001 per share 03/31/2025 0001662774 Quince Therapeutics, Inc. 22053A107 611 Gateway Boulevard Suite 273 South San Francisco CA 94080 Rule 13d-1(b) Sofinnova Capital VIII b I0 1197711.00 0.00 1197711.00 0.00 1197711.00 N 2.7 OO Note to Items 5 and 6: Sofinnova Partners SAS, a French corporation ("SP SAS"), the management company of Sofinnova Capital VIII ("SC VIII"), may be deemed to have sole voting power, and Antoine Papiernik ("Papiernik"), Henrijette Richter ("Richter"), Maina Bhaman ("Bhaman"), Graziano Seghezzi ("Seghezzi"), Anta Gkelou ("Gkelou"), and Karl Naegler ("Naegler") the members of the investment committee of SC VIII, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC VIII, may be deemed to have sole voting power, and Papiernik, Richter, Bhaman, Seghezzi, Gkelou, and Naegler, the members of the investment committee of SC VIII, may be deemed to have shared power to vote these shares. Sofinnova Partners SAS, a French Corporation b I0 1197711.00 0.00 1197711.00 0.00 1197711.00 N 2.7 OO Note to Items 5 and 6: SP SAS, the management company of SC VIII, may be deemed to have sole voting power, and Papiernik, Richter, Bhaman, Seghezzi, Gkelou and Naegler, the members of the investment committee of SC VIII, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC VIII, may be deemed to have sole power to dispose of these shares, and Papiernik, Richter, Bhaman, Seghezzi, Gkelou and Naegler, the members of the investment committee of SC VIII, may be deemed to have shared power to dispose of these shares. Antoine Papiernik b I0 1197711.00 0.00 1197711.00 0.00 1197711.00 N 2.7 IN Note to Items 5 and 6: SP SAS, the management company of SC VIII, may be deemed to have sole voting power, and Papiernik, a member of the investment committee of SC VIII, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC VIII, may be deemed to have sole power to dispose of these shares, and Papiernik, a member of the investment committee of SC VIII, may be deemed to have shared power to dispose of these shares. Henrijette Richter b G7 1197711.00 0.00 1197711.00 0.00 1197711.00 N 2.7 IN Note to Items 5 and 6: SP SAS, the management company of SC VIII, may be deemed to have sole voting power, and Richter, a member of the investment committee of SC VIII, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC VIII, may be deemed to have sole power to dispose of these shares, and Richter, a member of the investment committee of SC VIII, may be deemed to have shared power to dispose of these shares. Maina Bhaman b X0 1197711.00 0.00 1197711.00 0.00 1197711.00 N 2.7 IN Note to Items 5 and 6: SP SAS, the management company of SC VIII, may be deemed to have sole voting power, and Bhaman, a member of the investment committee of SC VIII, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC VIII, may be deemed to have sole power to dispose of these shares, and Bhaman, a member of the investment committee of SC VIII, may be deemed to have shared power to dispose of these shares. Graziano Seghezzi b I0 1197711.00 0.00 1197711.00 0.00 1197711.00 N 2.7 IN Note to Items 5 and 6: SP SAS, the management company of SC VIII, may be deemed to have sole voting power, and Seghezzi, a member of the investment committee of SC VIII, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC VIII, may be deemed to have sole power to dispose of these shares, and Seghezzi, a member of the investment committee of SC VIII, may be deemed to have shared power to dispose of these shares. Anta Gkelou b J3 1197711.00 0.00 1197711.00 0.00 1197711.00 N 2.7 IN Note to Items 5 and 6: SP SAS, the management company of SC VIII, may be deemed to have sole voting power, and Gkelou, a member of the investment committee of SC VIII, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC VIII, may be deemed to have sole power to dispose of these shares, and Gkelou, a member of the investment committee of SC VIII, may be deemed to have shared power to dispose of these shares. Karl Naegler b 2M 1197711.00 0.00 1197711.00 0.00 1197711.00 N 2.7 IN Note to Items 5 and 6: SP SAS, the management company of SC VIII, may be deemed to have sole voting power, and Naegler, a member of the investment committee of SC VIII, may be deemed to have shared power to vote these shares. Note to Items 7 and 8: SP SAS, the management company of SC VIII, may be deemed to have sole power to dispose of these shares, and Naegler, a member of the investment committee of SC VIII, may be deemed to have shared power to dispose of these shares. Quince Therapeutics, Inc. 611 Gateway Blvd., Suite 273, South San Francisco, Ca 94080 The persons and entities filing this Schedule 13G/A are Sofinnova Capital VIII ("SC VIII"), Sofinnova Partners SAS ("SP SAS"), Antoine Papiernik ("Papiernik"), Henrijette Richter ("Richter"), Maina Bhaman ("Bhaman"), Graziano Seghezzi ("Seghezzi"), Anta Gkelou ("Gkleou"), and Karl Naegler ("Naegler"), the members of the investment committee of SC VIII (together with SC VIII and SP SAS, the "Filing Persons"). SP SAS is the management company of SC VIII. The address of the principal place of business for each of the Filing Persons is Sofinnova Partners SAS, 7-11 boulevard Hausmann 75009 Paris, France. SC VIII is a French Partnership. SP SAS is a French Corporation. Papiernik is a French citizen. Richter is a Danish citizen. Bhaman is a British citizen. Seghezzi is a French citizen. Gkelou is a Greek citizen. Naegler is a German citizen. N FI Investment Adviser See Row 9 of the cover page for each of the Filing Persons. The filing of this Schedule 13G/A shall not be construed as an admission by Papiernik, Richter, Bhaman, Seghezzi, Gkelou, and Naegler that such person is, for the purposes of Section 13(d) of the Securities Exchange Act of 1934, the beneficial owner of any securities covered by this Statement. See Row 11 of the cover page for each of the Filing Persons. Ownership is stated as of March 31, 2025 and the ownership percentages are based on 44,001,643 shares outstanding as of March 13, 2025, as disclosed by Quince Therapeutics, Inc. in its Annual Report on Form 10-K filed with the SEC on March 24, 2025. See Row 5 of the cover page for each of the Filing Persons. See Row 6 of the cover page for each of the Filing Persons. See Row 7 of the cover page for each of the Filing Persons. See Row 8 of the cover page for each of the Filing Persons. N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to Investment Advisers is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution(s). I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D. Exhibit 1 - Joint Filing Agreement Sofinnova Capital VIII /s/ Antoine Papiernik 04/30/2025 Sofinnova Partners SAS, a French Corporation /s/ Antoine Papiernik 04/30/2025 Antoine Papiernik /s/ Antoine Papiernik 04/30/2025 Henrijette Richter /s/ Henrijette Richter 04/30/2025 Maina Bhaman /s/ Maina Bhaman 04/30/2025 Graziano Seghezzi /s/ Graziano Seghezzi 04/30/2025 Anta Gkelou /s/ Anta Gkelou 04/30/2025 Karl Naegler /s/ Karl Naegler 04/30/2025